10 citations
,
September 2014 in “European Journal of Dermatology” This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.
17 citations
,
February 2011 in “Expert Opinion on Drug Safety” This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.
January 2014 in “대한피부과학회지” This case study in a hepatitis B patient observed that pegylated interferon alpha2a treatment may induce localized alopecia areata, which appeared to correlate with treatment administration and discontinuation.
39 citations
,
January 2008 in “World Journal of Gastroenterology” This report documents the first known case of acute inflammatory demyelinating polyneuropathy potentially linked to pegylated interferon-alpha 2a in a woman undergoing treatment for chronic hepatitis C.
November 2022 in “JAAD case reports” This report diagnosed a 68-year-old man with comedonal folliculotropic mycosis fungoides based on clinical and histopathological findings, and found pegylated interferon alpha-2a with isotretinoin beneficial in reducing skin lesions.
1 citations
,
January 2014 in “Hair therapy & transplantation” This case study reports the first extensively interpreted instance of dystrophic telogen effluvium potentially linked to pegylated interferon and ribavirin therapy for chronic hepatitis C, characterized through clinical and trichogram analysis.
41 citations
,
August 2007 in “European Journal of Gastroenterology & Hepatology” This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.
176 citations
,
June 2016 in “PLoS ONE” In these initial clinical studies, NAP monotherapy showed significant reductions in HBsAg levels among patients with chronic HBV, suggesting potential as part of future combination therapies.
3 citations
,
March 2014 in “Annals of Hepatology” This case report describes irreversible alopecia universalis following discontinuation of Peg-IFN/RBV treatment for chronic hepatitis C, highlighting potential autoimmune side effects of interferon-based therapies.
2 citations
,
January 2007 in “Acta Dermato Venereologica” In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.
27 citations
,
August 2010 in “Clinics in Dermatology” This article reviews the association between hepatitis C virus and systemic disorders like mixed cryoglobulinemia, highlighting potential autoimmune side effects from interferon-a2b treatments, and reports no new clinical results.
11 citations
,
October 2001 in “Dermatologic Clinics” In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.
27 citations
,
April 2005 in “Journal of Chemotherapy” This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.
107 citations
,
December 2003 in “Dermatologic Therapy” This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.
34 citations
,
April 2008 in “Journal of the European Academy of Dermatology and Venereology” This study reported that while lichen planus was not significantly linked to hepatitis C virus infection, pruritus, dry skin, and hair loss were more common in HCV patients post-interferon treatment.
34 citations
,
August 2002 in “British Journal of Dermatology” This study observed that two patients treated with interferon α-2b and ribavirin for chronic hepatitis C experienced complete and reversible straightening of their natural curly hair, which recurred with treatment resumption.
April 2021 in “Anatolian current medical journal :” This case report highlights that a patient developed alopecia areata following treatment with sofosbuvir and ribavirin for chronic hepatitis C.
March 2016 in “International Journal of Infectious Diseases” This study reported that peginterferon alpha-2a showed high early and sustained virologic response rates in Albanian hemodialyzed patients with hepatitis C, despite causing several adverse effects.
64 citations
,
January 2009 in “Canadian Journal of Gastroenterology” This review discusses various presentations of drug-induced cutaneous eruptions, particularly those associated with interferon and ribavirin, and reports no new clinical findings.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
15 citations
,
January 2014 in “Dermatology” This study found a relatively low prevalence of cutaneous reactions in chronic hepatitis C patients treated with peginterferon alfa and ribavirin, with reactions correlated to age and treatment duration.
24 citations
,
May 2012 in “International Journal of Dermatology” This review discusses the various causes and associations of eyelash trichomegaly, including congenital syndromes, acquired conditions, and drug effects, without reporting new clinical results.
10 citations
,
October 2010 in “Hepatology” This case study suggests that treatment with Pil-Food, intended for hair loss prevention, may have triggered postinfantile giant cell hepatitis with autoimmune characteristics, which showed a rapid and effective response to corticosteroid therapy.
3 citations
,
July 2017 in “Elsevier eBooks” This article reviews the identification and assessment of cutaneous drug reactions, emphasizing the importance of early recognition and the need for accurate diagnosis to prevent serious complications; it reports no new clinical results.
This study reports an increase in the frequency and variety of skin conditions associated with COVID-19, noting that milder cases often present with pernio-like lesions, while severe cases may involve livedo racemosa, retiform purpura, and acral ischemia.
12 citations
,
June 2019 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” This article reviews the dermatological side effects of chemotherapy, their impact on treatment and patient quality of life, and emphasizes collaboration between oncologists and dermatologists for effective management.
9 citations
,
August 2024 in “Pharmacological Reviews” This review summarized advancements in intestinal lymphatic drug delivery, emphasizing the evolving understanding of lymphatics as active players in health and disease, which has led to innovative therapeutic strategies and enhanced pharmacokinetic outcomes via this delivery route.
9 citations
,
December 2022 in “Phytomedicine” This review discusses the pharmacology, toxicology, and clinical efficacy of flavonoids and saponins, highlighting the need for more data on their pharmacokinetics, interactions, and toxicities as most research is still in vitro.
2 citations
,
May 2024 in “Australasian Journal of Dermatology” Early diagnosis, innovative treatments, and considering systemic conditions are crucial in dermatological care.
52 citations
,
February 2003 in “Archives of dermatology” In this open-label trial, 9-cis-retinoic acid showed moderate activity against Kaposi sarcoma in AIDS patients, but its use is limited by substantial side effects at higher doses.